Introduction: Addressing the Progressive Challenge of MacTel Type 2
Macular telangiectasia type 2 (MacTel) is a progressive, bilateral neurodegenerative disease of the central retina that typically manifests in middle age. Characterized by the loss of Müller cells and subsequent degeneration of photoreceptors, MacTel leads to significant visual impairment, particularly affecting reading and fine-detail tasks. Unlike many other retinal diseases, MacTel does not primarily stem from vascular leakage or neovascularization in its early stages, making traditional anti-VEGF therapies largely ineffective for the non-proliferative form of the disease.
The quest for a neuroprotective agent that can stabilize the retina and prevent the loss of photoreceptors has led to the development of NT-501 (Revakinagene taroretcel). This innovative therapy utilizes encapsulated cell technology to provide a continuous, intraocular supply of ciliary neurotrophic factor (CNTF). Following promising results in Phase 2 clinical trials, two identical Phase 3 trials—NTMT-03-A and NTMT-03-B—were conducted to evaluate the efficacy and safety of NT-501 in slowing the progression of MacTel.
